Table 2:
Clinical outcomes and treatment effect in subjects in the ESCAPE trial with last seen healthy to randomization time of >5.5 hours
| Outcome | Intervention (n = 33) | Control (n = 26) | Risk Difference (Absolute) | P Value | Risk Ratio Unadjusted (95% CI) |
|---|---|---|---|---|---|
| mRS at 90 days, (median) (IQR) | 3 (3) | 4 (3) | – | .029a | – |
| mRS 0–2 at 90 days | 48.5% (16/33) | 29.2% (7/24) | 19.3% | .178 | 1.7 (0.8–3.4) |
| mRS 0–1 at 90 days | 39.3% (13/33) | 20.1% (5/24) | 18.6% | .161 | 1.89 (0.8–4.6) |
| NIHSS score 0–2 at 90 days | 45.5 (15/33) | 13.6 (3/22) | 31.8% | .019 | 3.33 (1.1–10.2) |
| ICH any (all types) | 48.5% (16/33) | 11.5% (3/26) | 36.9% | .004 | 4.2 (1.4–12.9) |
| ICH symptomatic | 0% | 0% | 0% | 1.000 | – |
| mTICI 2b-3 (EVT group) or mAOL 2–3 (control group)b | 87.5% (28/32) | 13.0% (3/23) | 74.5% | – | – |
Note:—mTICI indicates modified Thrombolysis in Cerebral Infarction score; mAOL, modified Arterial Occlusive Lesion score; EVT, endovascular treatment.
a
Parametric test of medians.
b
Reperfusion assessed as mTICI 2b–3 at end of EVT in the intervention group or as recanalization with mAOL score 2–3 on repeat CTA in the control group.